Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Clinical trial NCT04397003 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04397003
- Sponsor
- Washington University School of Medicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-30
- Primary completion
- 2027-09-30
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.